Download Curriculum Vitae

CURRICULUM VITAE
Xiaojia (Sasha) Guo, PH.D.
Yale School of Medicine, New Haven, CT 06520.
(203) 932-5711, x5238, [email protected]
PROFILE
A scientist with extensive experience in cancer research, biochemistry, molecular and cell biology. Well
versed in genomics, drug metabolism, and tumor models. Skilled at drug target assessment and
bioinformatic tools. Experienced in Biomarker and MOA study.
PROFESSIONAL EXPERIENCE
Yale University, New Haven, CT
2005 to Present
Associate Research Scientist – Yale School of Medicine
Responsible for development of multiple projects. Other responsibilities included managing of research
assistants, aiding principle investigator through manuscript and grant preparation, training postdoctoral
fellows, and laboratory management.
CuraGen Corporation, Branford, CT (a genomic-based biotech company)
2000 to 2005
Championed drug targets through the validation and development pipeline. Developed and validated in
vitro and in vivo assays for protein and antibody drug validation.
Senior Research Scientist – Drug Development Group (2002-2005)
Screened CuraGen proprietary genes for drug targets of antibody and protein therapy: developed and
evaluated peptide antibodies, delivered 12 targets to Oncology, Inflammation, and Metabolic groups;
Generated and analyzed DNA microarrays for cancers from pancreas, ovary, stomach, and lung; Carried
biomarker study for FGF20 and PDGF D; Served as a liaison between Drug Discovery and Operation
departments, eliminated bottleneck of cloning by giving correct sequence prediction of all elected targets,
tracked and coordinated DNA cloning and protein expression; Studied mechanism of actions for 2
preclinical drug targets by DNA and protein expression profiling.
Research Scientist – Drug Discovery Group (2000-2002)
Annotated pharmaceutical tractable genome: discovered and wrote provisional patent applications on
236 novel genes/splice variants, 14 of them became elected projects later; Performed high through put
data analysis of DNA sequences; Designed RTQ-PCR probes for gene expression profiling of druggable
genes; Designed in frame cloning for protein expression of elected target genes; Designed baits for
yeast two hybrid system and analyzed protein-protein interactions.
Cornell University Medical College, New York, NY
1994 to 2000
Postdoctoral Research Fellow – Dept. of Pharmacology
Examined in vitro and in vivo drug metabolism of retinoids; Investigated the effect of retinoids together
with TSA in cancer cells and in animal model; Examined the expression of retinoid receptors (RARs,
RXRs, CRBP, CRABP-I and II), LRAT, and P450 Cyp26 in various solid tumors and cancer cells; Studied
enzymology of LRAT, cloned human P450 Cyp26 gene, established stable cell lines over expressing
LRAT and Cyp26; Examined the role of keratin 19 during tumorigenesis using mouse tumor model and
knockout mice
Rutger’s University (State Univ. of New Jersey), Piscataway, New Jersey
1990-1994
Research Associate - Laboratory of Dr. David T. Denhardt
Examined gene regulation of osteopontin by ras oncogene, estrogen and androgen; Made transgenic
mice to examine the expression of osteopontin during embryogenesis; Identified a ras-response element
in the osteopontin gene promoter; Partially characterized and purified the ras-response element-binding
proteins
London Regional Cancer Research Center, London, Ont. Canada
1989-1990
Research Associate - Laboratory of Dr. Ann F. Chambers
Established Ras-transformed cell lines; Selected metastatic lines through chick embryo assays;
Performed transient transfection and CAT assay
University Of Western Ontario, London, Ontario, Canada
Research Assistant – Cancer Research Laboratory
Searched for cell cycle regulated genes, cloned and sequenced mouse calcyclin
1987-1989
EDUCATION
10/2000
Postdocteral, Pharmacology, Cornell Univ Medical College, New York, NY
05/1994
Ph.D., Cell Biology and Development, Rutgers University, NJ
05/1990
M.Sc., Biochemistry, University of Western Ontario, London, Ontario, Canada
HONORS AND AWARDS
1986-1990
International Youth Year Special Studentship Award, MRC of Canada
1991-1992
The Anne B. and James H. Leathem Scholarship Fund, Rutgers Univers
1995-1998
NIH postdoctoral fellowship, National Institute of Health
1998-2000
Breast Cancer Research fellowship, New York State Dept. of Health
2000-2001
Traineeship Award, U.S. Army Medical Research and Material Command
2011-2012
OHSE Award, Dept of Surgery, Yale Medical School
2012 – 2013
OHSE Award, Dept of Surgery, Yale Medical School
2013 -2014
OHSE Award, Dept of Surgery, Yale Medical School
ISSUED PATENT
1. Gudas, Lorraine J.and Guo, Xiaojia: Detection of epithelial cell cancers and precancerous
conditions. Patent No: US6,706,506. Issue Date: March 16, 2004
2. Anderson, David W.; …; Guo, Xiaojia; et al., Therapeutic polypeptides, nucleic acids encoding
same, and methods of use. Patent No: US 6,974,684 B2. Issue Date: 12/13/2005
3. Anderson, David W.; …; Guo, Xiaojia; et al. Therapeutic polypeptides, nucleic acids encoding
same, and methods of use. Patent No: US 7,034,132 B2. Issue date: 4/25/2006
PUBLISHED PATENT APPLICATIONS
WO02081517, WO02098917, WO02081518, WO02064791, WO02057452, WO02055704, WO0246408,
WO02062999, WO02066643, WO0244211, WO0246409, WO0233087, WO0161009, 0043382, 0009480,
0005576, 0005557, 0030236389, 0040052806, 0014687
RESEARCH SUPPORTS
Agency: Yale University School of Medicine
I.D.# Ohse Foundation Research Award
Title: “Role of Adrenomedullin 2 in tumor angiogenesis using a knockout mouse model”
P.I.: Xiaojia Guo
Percent effort: 5%
Direct costs per year: $32,000
Total costs for project period: $32,000
Project period: 2013-2014
Agency: Yale University School of Medicine
I.D.# Ohse Foundation Research Award
Title: “Role of Adrenomedullin 2 in Breast Cancer”
P.I.: Xiaojia Guo
Percent effort: 5%
Direct costs per year: $40,000
Total costs for project period: $40,000
Project period: 2013-2014
Agency: Yale University School of Medicine
I.D.# Ohse Foundation Research Award
Title: “Role of Intermedin in Hepatocellular Carcinoma”
P.I.: Xiaojia Guo
Percent effort: 5%
Direct costs per year: $20,000
Total costs for project period: $20,000
Project period: 2011-2012
PUBLICATIONS
1. Guo X, Chambers AF, Parfett CL, Waterhouse P, Murphy LC, Reid RE, Craig AM, Edwards DR,
Denhardt DT. Identification of a serum-inducible messenger RNA (5B10) as the mouse homologue of
calcyclin: tissue distribution and expression in metastatic, ras-transformed NIH 3T3 cells. Cell Growth
Differ. 1990 1(7):333-8.
2. Waterhouse P, Parhar RS, Guo X, Lala PK, Denhardt DT. Regulated temporal and spatial expression
of the calcium-binding proteins calcyclin and OPN (osteopontin) in mouse tissues during pregnancy. Mol
Reprod Dev. 1992 32(4):315-23.
3. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993 7(15):1475-82.
4. Guo X, Zhang YP, Mitchell DA, Denhardt DT, Chambers AF. Identification of a ras-activated enhancer
in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor
whose activity correlates with the metastatic potential of the cell. Mol Cell Biol. 1995 15(1):476-87.
5. Chen AC, Guo X, Derguini F, Gudas LJ. Human breast cancer cells and normal mammary epithelial
cells: retinol metabolism and growth inhibition by the retinol metabolite 4-oxoretinol. Cancer Res. 1997
Oct 15; 57(20):4642-51.
6. Guo X, Gudas LJ. Metabolism of all-trans-retinol in normal human cell strains and squamous cell
carcinoma (SCC) lines from the oral cavity and skin: reduced esterification of retinol in SCC lines. Cancer
Res. 1998 1;58(1):166-76.
7. Vanacker JM, Delmarre C, Guo X, Laudet V. Activation of the osteopontin promoter by the orphan
nuclear receptor estrogen receptor related alpha. Cell Growth Differ. 1998 9(12):1007-14.
8. Guo X, Ruiz A, Rando RR, Bok D, Gudas LJ. Esterification of all-trans-retinol in normal human
epithelial cell strains and carcinoma lines from oral cavity, skin and breast: reduced expression of
lecithin:retinol acyltransferase in carcinoma lines. Carcinogenesis. 2000 21(11):1925-33.
9. Guo X, Morris P, Gudas L. Follicle-stimulating hormone and leukemia inhibitory factor regulate Sertoli
cell retinol metabolism. Endocrinology. 2001 142(3):1024-32.
10. Guo X, Nanus DM, Ruiz A, Rando RR, Bok D, Gudas LJ. Reduced levels of retinyl esters and vitamin
A in human renal cancers. Cancer Res. 2001 15;61(6):2774-81.
11. Guo X, Knudsen BS, Peehl DM, Ruiz A, Bok D, Rando RR, Rhim JS, Nanus DM, Gudas LJ. Retinol
metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells
and tissue specimens. Cancer Res. 2002 Mar 15;62(6):1654-61.
12. Cerignoli F, Guo X, Cardinali B, Rinaldi C, Casaletto J, Frati L, Screpanti I, Gudas LJ, Gulino A,
Thiele CJ, Giannini G. retSDR1, a short-chain retinol dehydrogenase/reductase, is retinoic acid-inducible
and frequently deleted in human neuroblastoma cell lines. Cancer Res. 2002 Feb 15; 62(4):1196-204.
13. Touma SE, Goldberg JS, Moench P, Guo X, Tickoo SK, Gudas LJ, Nanus DM. Retinoic acid and the
histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a
xenograft tumor model. Clin Cancer Res. 2005 May 1;11(9):3558-66.
14. Zhang J, Ahmed M, Nie L, Asadi A,Dobrucki LW, Esmailzadeh L, Guo X, Edwards S, Michael Azure
M, Sinusas AJ, Sadeghi MM. Circulation. 2006 114: II_500.
15. Sadeghi MM, Esmailzadeh L, Zhang J, Guo X, Asadi A, Krassilnikova S, Fassaei HR, Luo G, AlLamki RS, Takahashi T, Tellides G, Bender JR, Rodriguez ER. ESDN is a marker of vascular remodeling
and regulator of cell proliferation in graft arteriosclerosis. Am J Transplant. 2007 Sep; 7(9):2098-105.
16. Guo X, Nie L, Esmailzadeh L, Zhang J, Bender JR, Sadeghi MM. Endothelial and smooth musclederived neuropilin-like protein regulates platelet-derived growth factor signaling in human vascular
smooth muscle cells by modulating receptor ubiquitination. J Biol Chem. 2009 Oct 23; 284(43):29376-82.
17. Guo X., Schmitz J., Uchio E., Kenney B., Kulkarni S., and Cha C, Intermedin is Highly Expressed in
Hepatocellular Carcinoma and Regulates Cell Proliferation and Survival. Cancer Sci. 2012 Aug;
103(8):1474-80.
18. Nicholson A, Guo X, Sullivan C, Cha CH. Loss of Bcl-2 expression impacts survival in colorectal
cancer using a high throughput tissue microarray analysis (AQUA). J.Am Col Surgeons 2012 Sept
215(3):127.
19. Nicholson A, Bishop J, Lannin D, Killelea B, Guo X, Cha C, Dixon JM. Triple-negative breast cancer:
molecular characterization and targeted therapies. Breast Cancer Manage. 2013 2(5): 417–430
20. Nie L, Guo X, Esmailzadeh L, Zhang J, Asadi A, Collinge M, Li X, Kim J-D, Woolls M, Jin S-W,
Dubrac A, Eichmann A, Simons M, Bender JR, Sadeghi MM. ESDN modulates angiogenesis and
regulates VEGF signaling in endothelial cells. J. Clinical Investigation 2013 Dec 2;123(12):5082-97
21. Nicholson A, Guo X, Sullivan C, Cha CH. Automated Quantitative Analysis of Tissue Microarray of
443 Patients with Colorectal Adenocarcinoma: Low Expression of Bcl-2 Predicts Poor Survival. J. Am Coll
Surg. 2014 Nov 219 (5): 977-987
22. Guo X, Wang L, Velazquez H, Safirstein R, and Desir GV. Renalase: its role as a cytokine, and an
update on its association with type 1 diabetes and ischemic stroke. Curr Opin Nephrol Hypertens. 2014
Sept 23(5): 513-518
23. Hollander LL, Guo X, Salem R, Cha C. The Novel Tumor Angiogenic Factor, Adrenomedullin-2
(ADM2) Predicts Survival in Pancreatic Adenocarcinoma. J Surg Res. 2015 Aug 197 (2): 219-224
24. Hollander LL, Guo X, Salem R, Cha C. Neoadjuvant Chemotherapy in Pancreatic Cancer in the Age
of FOLFIRINOX. Submitted, World Journal of Gastrointestinal Oncology.